Description
A Phase 3 Randomized Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma Who Have Received 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Monoclonal Antibody and Lenalidomide (MajesTEC-9)
Location: REDI (East Bay)
Contact: Piante' Berniard or 510.204.3428
Principal Investigator
Co-Investigator(s)
Related Studies
Coverage, Price, and Reimbursement for Multigene Tests for Cancer and Related Conditions
Investigator: Su-Ying Liang, Ph.D.
Improving Cancer Care
Investigator: Su-Ying Liang, Ph.D.
Multilevel Study of Lung Cancer Screening Guidelines Implementation (MUST)
Investigator: Jiang Li, Ph.D., MPH
Implementing Universal Lynch Syndrome Screening Across Multiple Healthcare Systems: Identifying Strategies to Facilitate and Maintain Programs in Different Organizations Contexts
Investigators: External PI, Principal Investigator, Su-Ying Liang, Ph.D., Monique de Bruin, M.D., MPH
Lung Cancer in Never Smokers: Incidence, Risk Factors and Molecular Characteristics in Asian American, Native Hawaiian, and Pacific Islander (AANHPI) Women
Investigators: External PI, Principal Investigator, Su-Ying Liang, Ph.D.
Using Electronic Health Records to Understand Pathways of Breast Cancer Screening and Care
Breast Cancer Chemoprevention in Primary Care at Geisinger
Investigators: Xiaowei (Sherry) Yan, PhD, MS, External PI, Principal Investigator